Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Status:
Recruiting
Trial end date:
2023-05-27
Target enrollment:
Participant gender:
Summary
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety,
pharmacokinetics, and preliminary activity of ASTX295 in subjects with wild-type TP53
advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design followed
by a Phase 2 study.